Article Information
History
- July 7, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Dena Zeraatkar, methodologist1,2,
- Ellen Cusano, internist3,
- Juan Pablo Díaz Martinez, methodologist2,
- Anila Qasim, methodologist2,
- Sophia O. Mangala, methodologist2,
- Elena Kum, methodologist2,
- Jessica J. Bartoszko, methodologist2,
- Tahira Devji, methodologist2,
- Thomas Agoritsas, internist, methodologist2,12,13,
- Francois Lamontagne, critical care physician, methodologist14,15,
- Bram Rochwerg, critical care physician, methodologist2,17,
- Per O Vandvik, internist, methodologist13,19,
- Romina Brignardello-Petersen, methodologist2 and
- Reed Siemieniuk, internist, methodologist*,2
- 1Department of Biomedical Informatics, Harvard Medical School
- 2Department of Health Research Methods, Evidence, and Impact, McMaster University
- 3Cumming School of Medicine, University of Calgary
- 12Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva
- 13MAGIC Evidence Ecosystem Foundation, Oslo
- 14Department of Medicine, University of Sherbooke, Sherbrooke, Quebec
- 15Centre de recherche du CHU University of Sherbooke, Sherbrooke, Quebec
- 17Department of Medicine, McMaster University
- 19Department of Health Economics and Health Management, Institute for Health and Society, University of Oslo, Oslo
- ↵*Corresponding author: Reed Siemieniuk (reed.siemieniuk{at}medportal.ca)
Authors’ Contributions: DZ, BR, FL, TA, POV, RBP, and RS conceived the study. JB identified studies. DZ, EC, and EK collected the data. AQ and JPDM analyzed the data. TD and RBP assessed the certainty of evidence. DZ drafted the first version of this manuscript.
Posted July 07, 2021.
Tocilizumab and sarilumab alone or in combination with corticosteroids for COVID-19: A systematic review and network meta-analysis
